EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ZYME: Zymeworks Inc

02 Dec 25 15:59
LAST:

25.10

CHANGE:
 0.93		OPEN:
25.98		HIGH:
26.66		ASK:
0.00		VOLUME:
764.3K
CHG(%):
3.57		PREV:
26.03		LOW:
24.83		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
02 Dec 2526.1226.6624.8325.101.2M
01 Dec 2526.4626.9125.8026.03830.8K
28 Nov 2527.4527.6926.4126.71578.1K
26 Nov 2526.2528.4926.1827.332.2M
25 Nov 2525.0126.2124.7426.181.64M
24 Nov 2524.3025.0023.9924.992.65M
21 Nov 2523.8225.0023.7724.021.69M
20 Nov 2523.0023.9822.8923.821.54M
19 Nov 2523.0023.0121.8922.601.94M
18 Nov 2524.2824.5022.0522.993.66M

PROFILE

Name:Zymeworks Inc
About:Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Sector:Healthcare
Industry:Biotechnology
Address:108 Patriot Drive, Middletown, DE, United States, 19709
Website:https://www.zymeworks.com
CUSIP:98985W102
CIK:0001403752
ISIN:US98985Y1082
FIGI:BBG019XSYC89

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:3.79 
Forward P/E:-11.36 
PEG Ratio:-0.04 
Price to Sales:11.76 
Price to Book:4.27 
Profit Margin:-0.60 
Operating Margin:-0.01 
Return on Assets:-0.11 
Return on Equity:-0.20 
EPS Ratio:-0.98 
Revenue:122.87M 
Shares:75.17M 
Market Cap:1.887B 

TECHNICAL INDICATORS

MA5:26.274.7%
MA10:24.980.5%
MA20:21.9214.5%
MA50:19.3829.5%
MA100:16.8049.4%
MA200:14.5372.8%
STO9:42.44
STO14:66.07
RSI14:68.26 
WPR14:-25.25
MTM14:5.73
ROC14:0.30 
ATR:1.83 
Week High:28.4913.5%
Week Low:24.741.5%
Month High:28.4913.5%
Month Low:16.0072.8%
Year High:28.4913.5%
Year Low:9.03178.0%
Volatility:45.67